Highlights

  • ResMed (ASX:RMD) launched the AirTouch F40 fabric full-face CPAP mask in the United States.
  • September-quarter FY27 Revenue increased 6% to USD 1.415 billion.
  • The quarter delivered GAAP Diluted Earnings per Share of USD 2.92, up 23%.
  • October guidance maintained FY27 reported revenue of USD 5.75–5.85 billion.

ResMed (ASX:RMD) manufactures connected devices, masks and software for sleep apnoea, respiratory care and home-health management across international markets. Its October product introduction and September-quarter results give separate views of product development and financial performance. On 20 November 2026, its ASX securities traded at AUD 35.55, down 2.36% during the session.

The company released its first-quarter FY27 results on 29 October and held its virtual annual stockholders meeting in November. The newest reported quarter ended on 30 September, meaning the announcement was retrospective rather than a forecast for the remaining financial year.

October Mask Launch Broadens the Portfolio

In October the company announced the US introduction of the AirTouch F40 full-face fabric continuous positive airway pressure mask. The launch extends its mask range for patients using prescribed sleep-apnoea therapy.

Mask design and fit are relevant to comfort and adherence, but announcement of a product does not provide a quantified sales contribution. Clinical prescription, reimbursement, distribution arrangements and patient selection influence actual use. Future product-level disclosures, where supplied, would be needed to establish a commercial effect.

September Quarter Shows Device and Software Demand

Revenue increased 6% to USD 1.415 billion in the quarter ended September 2026; management reported 7% growth on a core constant-currency basis. GAAP diluted earnings per share reached USD 2.92, up 23%, while non-GAAP diluted earnings per share were USD 2.91, up 14%.

These two earnings measures use different accounting adjustments. The non-GAAP figure should not be presented as an alternative statutory result. Management also reported returning more than USD 1.0 billion through dividends and share repurchases during the quarter, a capital-management activity distinct from revenue growth.

FY27 Outlook and Business Scope

The October results release retained reported revenue guidance of USD 5.75 billion to USD 5.85 billion for FY27, with core constant-currency growth expected at 5–7%. The non-GAAP diluted earnings-per-share range remained USD 12.00 to USD 12.25.

The company’s products combine hardware, recurring mask purchases and connected data services. These components can have different purchasing and subscription profiles. Monitoring them separately can clarify the drivers of reported revenue without relying on assumptions about patient numbers or prescribing trends.

Portfolio Changes and Capital Allocation

ResMed also disclosed the closing of the previously announced MatrixCare divestiture during the quarter. This means changes in reported activities should be interpreted with attention to the scope of the continuing portfolio. Its October results separately recorded non-GAAP Operating Income of USD 506 million and GAAP operating income of USD 453 million. The distinction between accounting measures remains relevant when comparing operating margins.

Risks to Consider

Market access, reimbursement policies, product reliability and competing device designs are relevant operating considerations. Foreign currency movements can affect reported sales, while component costs and logistics influence gross margin.

What to Watch Next

Subsequent quarterly results can test the unchanged FY27 revenue and earnings ranges. Product updates can indicate whether the AirTouch F40 has expanded geographically and whether any additional patient-use evidence has been released.

Capital returns should be reviewed alongside operating cash generation and Investment in connected devices and software. The company’s next reporting cycle is the appropriate point to reassess quarterly results and financial guidance.

Key Insights

The October mask introduction and September-quarter accounts provide different measures of progress. Reported revenue, earnings measures and FY27 guidance can be evaluated alongside product adoption and patient access, without inferring a causal relationship with daily share trading.